Skip to main content
All lobbying filings

ECOLAB INC.

Lobbying for ECOLAB INC

 Filing 2nd Quarter - Amendment
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Aug 6, 2025
Expenses
$430,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 8
  • Commerce, Dept of (DOC)
  • Energy, Dept of
  • Environmental Protection Agency (EPA)
  • Executive Office of the President (EOP)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE
  • State, Dept of (DOS)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 5
Environment/Superfund

Discussions related to environmental policies and issues including water infrastructure, water reuse, water efficiency, water resource management, and sustainability. Discussions related to energy and water efficiency initiatives. Discussions related to PFAS remediation technology. Discussions related to the implementation of the Pesticide Registration Improvement Act, P.L.117-103. Discussions related to data center water efficiency and energy efficiency.

Taxation/Internal Revenue Code

Discussions regarding scope of Sec. 48D investment tax credit; Discussions related to the extension of the Tax Cuts and Jobs Act (P.L.115-97); H.R.1, One Big Beautiful Bill Act.

Trade (domestic/foreign)

Discussions related to supply chain challenges. Discussions regarding trade policy and tariffs.

Energy/Nuclear

Discussions regarding sustainable aviation fuel. Discussions regarding permitting reform. Discussions regarding Department of Energy programs for Critical Mineral production, including the use of resins as extraction technology.

Pharmacy

Discussions regarding biopharmaceutical manufacturing policy. Discussions regarding resin bead manufacturing technology.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem